Predict your next investment

Venture Capital
tateandlyleventures.com

See what CB Insights has to offer

Investments

20

Portfolio Exits

4

Funds

2

Service Providers

1

About Tate & Lyle Ventures

Tate & Lyle Ventures consists of two venture capital funds, a £25 million venture capital fund launched in 2006 (and now fully committed) and an active £30 million fund focused on investing in high growth companies in the areas of food sciences and technologies. Both funds are structured and managed as Limited Partnerships enabling them to be managed as independent venture capital funds. Tate & Lyle Ventures is structured in this way to enable objective investment decisions to be made rapidly and independently based on best practice in the venture capital industry.

Tate & Lyle Ventures Headquarter Location

1 Kingsway

London, England, WC2B 6AT,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Tate & Lyle Ventures News

Zacks Investment Research Lowers Tate & Lyle (OTCMKTS:TATYY) to Strong Sell

Jul 27, 2020

Zacks Investment Research Lowers Tate & Lyle (OTCMKTS:TATYY) to Strong Sell Posted by Erica Schwartz on Jul 27th, 2020 Daily Ratings & News for Tate & Lyle Complete the form below to receive the latest headlines and analysts' recommendations for Tate & Lyle with our free daily email newsletter: Zacks Investment Research lowered shares of Tate & Lyle (OTCMKTS:TATYY) from a buy rating to a strong sell rating in a report issued on Thursday, Zacks.com reports. According to Zacks, “Tate & Lyle Ventures and Agri Investment Fund have co-led a 3.5m investment into Fugeia, a newly formed functional food technology business with a focus on gut health. “ Get Tate & Lyle alerts: Other equities analysts have also issued reports about the stock. Barclays reissued an overweight rating on shares of Tate & Lyle in a research report on Thursday, May 28th. Jefferies Financial Group raised shares of Tate & Lyle from a hold rating to a buy rating in a research report on Tuesday, March 31st. ValuEngine lowered shares of Tate & Lyle from a hold rating to a sell rating in a research report on Wednesday, May 27th. Investec lowered shares of Tate & Lyle from a hold rating to a sell rating in a research report on Wednesday, May 6th. Finally, Berenberg Bank reaffirmed a hold rating on shares of Tate & Lyle in a report on Wednesday, May 6th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $39.00. TATYY opened at $34.28 on Thursday. Tate & Lyle has a 12-month low of $23.57 and a 12-month high of $42.50. The company has a current ratio of 2.23, a quick ratio of 1.33 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $4.01 billion, a PE ratio of 11.58 and a beta of 0.78. The firm has a 50 day moving average of $33.53 and a two-hundred day moving average of $35.27. About Tate & Lyle Tate & Lyle PLC, together with its subsidiaries, provides ingredients and solutions to the food, beverage, and other industries in the United States, the United Kingdom, other European countries, and internationally. It operates through three segments: Food & Beverage Solutions, Sucralose, and Primary Products.

Tate & Lyle Ventures Investments

20 Investments

Tate & Lyle Ventures has made 20 investments. Their latest investment was in Zymtronix as part of their Unattributed VC on February 2, 2020.

CBI Logo

Tate & Lyle Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/5/2020

Unattributed VC

Zymtronix

Yes

1

8/12/2019

Series C

Nutriati

$12.7M

No

5

12/19/2018

Series A

Changing Health

$3.79M

Yes

4

6/13/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

5/18/2018

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/5/2020

8/12/2019

12/19/2018

6/13/2018

5/18/2018

Round

Unattributed VC

Series C

Series A

Series C

Series B

Company

Zymtronix

Nutriati

Changing Health

Subscribe to see more

Subscribe to see more

Amount

$12.7M

$3.79M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

5

4

10

10

Tate & Lyle Ventures Portfolio Exits

4 Portfolio Exits

Tate & Lyle Ventures has 4 portfolio exits. Their latest portfolio exit was Nutriati on May 03, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/3/2022

Acquired

3

9/15/2015

Acquired

Subscribe to see more

Subscribe to see more

10

11/18/2014

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

2/28/2013

Acquired

Subscribe to see more

Subscribe to see more

10

Date

5/3/2022

9/15/2015

11/18/2014

2/28/2013

Exit

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

Tate & Lyle Ventures Acquisitions

1 Acquisition

Tate & Lyle Ventures acquired 1 company. Their latest acquisition was BioFilm on January 03, 2008.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/3/2008

Other

$99M

$6.17M

Acq - Fin

1

Date

1/3/2008

Investment Stage

Other

Companies

Valuation

$99M

Total Funding

$6.17M

Note

Acq - Fin

Sources

1

Tate & Lyle Ventures Fund History

2 Fund Histories

Tate & Lyle Ventures has 2 funds, including Tate & Lyle Ventures.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/1/2006

Tate & Lyle Ventures

Early-Stage Venture Capital

Closed

$46M

1

Tate & Lyle Ventures II

Subscribe to see more

Subscribe to see more

10

Closing Date

4/1/2006

Fund

Tate & Lyle Ventures

Tate & Lyle Ventures II

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$46M

Sources

1

10

Tate & Lyle Ventures Service Providers

1 Service Provider

Tate & Lyle Ventures has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Tate & Lyle Ventures Team

2 Team Members

Tate & Lyle Ventures has 2 team members, including current Managing Partner, David Atkinson.

Name

Work History

Title

Status

David Atkinson

Managing Partner

Current

Simon Barnes

Managing Partner

Current

Name

David Atkinson

Simon Barnes

Work History

Title

Managing Partner

Managing Partner

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.